Management of Malignant Biliary Obstruction in Metastatic Non‑Small Cell Lung Cancer

Diagnostic Priorities

Severe intra‑ and extra‑hepatic biliary dilation (common hepatic duct ≈ 1.8 cm) together with markedly elevated cholestatic enzymes strongly indicates extrinsic compression at the porta hepatis rather than intra‑hepatic metastatic disease in patients with known metastatic NSCLC. 1
Acute cholangitis must be excluded promptly in any patient with biliary obstruction and systemic signs (e.g., leukocytosis, fever), especially after recent travel to endemic regions; obtain blood cultures before antibiotics. 2
IgG4‑related sclerosing cholangitis should be considered as a reversible inflammatory mimic of malignant obstruction; order serum IgG4 levels. 2
ERCP with biliary brushings/biopsy and simultaneous stent placement is the recommended first‑line procedure to obtain tissue diagnosis and relieve obstruction. 2
Comprehensive infectious work‑up (blood cultures, hepatitis A‑E serologies, stool ova/parasites for liver flukes) is advised before initiating therapy. 2

Start empiric broad‑spectrum antibiotics (e.g., piperacillin‑tazobactam or ceftriaxone + metronidazole) immediately if any component of Charcot’s triad is present, pending culture results. 2
Correct coagulopathy before ERCP by administering vitamin K (10 mg IV daily for 3 days) when INR ≥ 1.3. 2
Provide aggressive IV hydration (lactated Ringer’s) to maintain urine output > 0.5 mL/kg/h and reduce risk of hepatorenal syndrome. 2

Do not rechallenge pembrolizumab after a prior grade 3‑4 immune‑related pancreatitis, because recurrence of immune‑related adverse events occurs in up to 74 % of patients (≈ 20 % grade 3‑4). 3 – NCCN guideline.
Perform molecular profiling (including MSI‑H/dMMR testing) because pembrolizumab monotherapy yields an overall response rate of ~34 % in MSI‑H tumors across cancer types. [3][4]5 – NCCN guideline.
Resume pemetrexed maintenance only after biliary decompression and when bilirubin is < 3 × ULN and transaminases are improving, to avoid severe hepatotoxicity. 2

If malignant obstruction is confirmed, place a metal biliary stent (preferred for longer patency) and schedule repeat endoscopic evaluation every 3–4 months or as clinically indicated. 2
Consider palliative external‑beam radiation to the porta hepatis when bulky peri‑portal lymphadenopathy is the primary cause of obstruction. 1
Early referral to palliative‑care services is recommended to address symptom burden and quality‑of‑life concerns. 1

Check serum bilirubin, alkaline phosphatase, and transaminases daily until a consistent down‑trend is observed after decompression. 2
Monitor coagulation profile every 2–3 days, aiming for INR < 1.3 before any invasive procedure. 2
Assess renal function daily to detect early hepatorenal syndrome and to ensure safety of contrast‑based imaging. 2
Watch for clinical signs of recurrent cholangitis (fever, mental status change, hemodynamic instability); if suspected, arrange urgent repeat ERCP. 2

Biliary obstruction from metastatic disease markedly worsens prognosis, with median survival of 4–6 months if untreated. 1
Successful biliary decompression combined with continuation of pemetrexed maintenance can extend median overall survival to 12–20 months (based on maintenance‑therapy data). 1
Venous thromboembolism prophylaxis with enoxaparin 40 mg SC daily is essential, as pancreatic/biliary malignancies carry the highest VTE rates among cancers and VTE is the second leading cause of cancer‑related death. 1

Do not delay ERCP for additional imaging when biliary obstruction is evident; ERCP provides both diagnosis and therapy. 2
Avoid administering pemetrexed in the setting of severe hepatic dysfunction; hold until bilirubin < 3 × ULN. 2
Re‑challenging with pembrolizumab after a severe immune‑related adverse event is contraindicated due to high recurrence risk. 3 – NCCN guideline.
Always exclude treatable infectious etiologies (e.g., cholangitis, liver fluke infection) before attributing findings solely to malignancy. 2
Ensure adequate vitamin K replacement before invasive procedures when INR is elevated to prevent procedural bleeding. 2